Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Encompass Health Corporation’s (NYSE: EHC) SEC filings, offering detailed insight into the company’s inpatient rehabilitation hospital business and financial profile. As the largest owner and operator of inpatient rehabilitation hospitals in the United States, Encompass Health uses its filings to report operating results, liquidity measures and other material information.
Current reports on Form 8-K included in the available information show how the company discloses quarterly financial results, updates to full-year guidance and investor materials. These filings reference metrics such as net operating revenue, Adjusted EBITDA, adjusted earnings per share, leverage ratio and adjusted free cash flow, along with explanations of why non-GAAP measures are used and how they are reconciled to comparable GAAP figures.
Other 8-K filings address topics like publication of an Investor Reference Book, which provides an overview of the company and its industry, business outlook, growth strategy and operational initiatives, as well as Regulation FD communications when senior management meets with investors and analysts. Governance-related 8-Ks can also appear, such as notices of director departures.
Through this filings page, users can review Encompass Health’s earnings-related 8-Ks, Regulation FD disclosures and other material event reports as they are made available via EDGAR. AI-powered tools on the platform can help summarize lengthy documents, highlight key metrics and clarify definitions of non-GAAP measures like Adjusted EBITDA and adjusted free cash flow, making it easier to understand how the company evaluates performance, manages leverage and plans for growth.
For anyone analyzing EHC stock, these SEC filings are a primary source for understanding Encompass Health’s financial condition, risk disclosures, capital structure and strategic communications with investors.
Encompass Health (EHC) reported solid Q3 2025 results. Net operating revenues rose to $1,477.5 million from $1,351.0 million, and net income attributable to Encompass Health increased to $126.5 million from $108.2 million. Diluted EPS was $1.24 versus $1.06. Adjusted EBITDA reached $300.1 million, up from $269.3 million.
For the nine months, revenues were $4,390.6 million (vs. $3,968.2 million) with net income attributable to Encompass Health of $420.1 million (vs. $334.8 million). Year‑to‑date cash from operations was $829.6 million. The company redeemed the remaining $100 million of 5.75% Senior Notes due 2025 and ended the quarter with long‑term debt (net of current) of $2,393.9 million.
Operations expanded with new hospitals and bed additions across multiple states. Management expects the FY26 IRF rule to lift Medicare payment rates by approximately 2.9% effective October 1, 2025. The One Big Beautiful Bill Act is estimated to produce about $180 million of additional current deductions and approximately $50 million in 2025 cash tax savings. Shares outstanding were 100,615,977 as of October 21, 2025.
Encompass Health (EHC) furnished its third‑quarter 2025 results via a press release and supplemental materials attached as Exhibits 99.1 and 99.2 to an Item 2.02/7.01 Form 8‑K. The materials include definitions and reconciliations for non‑GAAP measures such as adjusted earnings per share, Adjusted EBITDA, leverage ratio, and adjusted free cash flow.
The company will discuss these results on an earnings call at 10:00 a.m. Eastern Time on Thursday, October 30, 2025. The furnished information is not deemed filed under the Exchange Act. The filing also details how the leverage ratio is calculated under the credit agreement and outlines the role of Adjusted EBITDA in covenant compliance and liquidity assessment, along with cautionary forward‑looking statements.
Encompass Health (EHC) director Greg D. Carmichael reported an automatic award of 23 restricted stock units (RSUs) on 10/15/2025. The filing shows these were credited at a $0 price as dividend-equivalent RSUs tied to the company’s common stock dividend program for non-employee directors.
According to the footnote, the RSUs credited equal the product of RSUs held on the dividend record date and the $0.19 per-share dividend, divided by the stock’s $123.65 closing price on the payment date. Following the transaction, the form lists 18,631 securities beneficially owned in direct form.
Encompass Health (EHC) reported a director’s Form 4 activity on 10/15/2025. The director received 7 RSUs credited in connection with a common stock dividend and acquired 223 shares through the Directors Deferred Stock Investment Plan.
The RSUs were credited based on the company’s $0.19 per share dividend and a closing price of $123.65. The 223 shares were purchased at a weighted average price of $123.21. Following these transactions, the director beneficially owns 6,904 shares directly.
Encompass Health (EHC) reported an insider equity award tied to its dividend policy. A company director acquired 73 restricted stock units at a stated price of $0 on October 15, 2025, reflecting dividend-equivalent RSUs credited under existing award agreements. Following the transaction, the director beneficially owned 47,752 shares/units directly.
The RSU credit was calculated using a $0.19 per-share dividend and the $123.65 closing price on the payment date, per the explanation of responses.
Encompass Health (EHC) reported an insider equity change: director Leslye G. Katz acquired 73 restricted stock units on 10/15/2025 at $0 per unit. The award reflects dividend-equivalent RSUs tied to a $0.19 common stock dividend, calculated using the $123.65 closing price on the payment date. Following the transaction, Katz beneficially owned 47,752 Encompass Health common shares.
Encompass Health (EHC) director Kevin J. O’Connor reported an automatic credit of 14 restricted stock units (RSUs) on 10/15/2025. The award reflects dividend equivalents under outstanding RSU agreements tied to the company’s common stock dividend.
Per the footnote, the number of RSUs credited equals the product of the RSUs held on the dividend record date and the $0.19 per-share dividend, divided by the $123.65 closing price on the dividend payment date. The transaction was recorded at $0. Following this entry, securities beneficially owned were listed as 9,895, held directly.
Encompass Health (EHC) director Form 4: On 10/15/2025, a non-employee director reported two acquisitions. First, 16 restricted stock units were credited at $0 pursuant to dividend-equivalent terms tied to outstanding RSUs. Second, 288 common shares were purchased at a weighted average price of $123.23 in multiple trades ranging from $123.19 to $123.24.
The RSU credit relates to a $0.19 per-share common dividend paid on October 15, 2025, using the closing price of $123.65 to calculate units. The share purchase reflects the Directors Deferred Stock Investment Plan, which uses deferred director fees and reinvested dividends to buy shares in the market. Following these transactions, direct beneficial ownership reported in Table I was 15,085 shares.
Encompass Health (EHC) director Nancy M. Schlichting reported an automatic credit of 33 restricted stock units (RSUs) on 10/15/2025. The award stems from dividend equivalents pursuant to outstanding RSU award agreements, reflecting Encompass Health’s common stock dividend of $0.19 per share and a closing price of $123.65 on the payment date. The transaction is recorded at $0 as it was an accrual, not a market purchase.
Following this transaction, Schlichting beneficially owns 21,219 shares, held directly.
Encompass Health (EHC) director Terrance Williams reported an automatic credit of 23 restricted stock units on 10/15/2025. The award reflects dividend-equivalent RSUs under outstanding agreements, calculated using a $0.19 per-share dividend and the $123.65 closing price on the dividend payment date. The transaction was recorded at $0 per unit. Following this entry, Williams beneficially owned 15,141 securities in direct ownership.